Influence of schedule and mode of administration on effectiveness of podofilox treatment of papillomas.
We investigated the timing of podofilox delivery to see how it correlated with papilloma size. We looked at times ranging from once per week (morning and afternoon) to five times per week (morning and afternoon). We also looked at delivery systems that might enhance the effectiveness of the drug by increasing penetration of the overlying cutaneous horn. These included soaking prior to drug administration, the use of a grooved needle subsequent to drug administration, and the various possible combinations of these techniques. We found that the timing of treatments had relatively little effect on the size of the papillomas. For example, at the end of ten weeks, the geometric mean diameter (GMD) (mm) of the papillomas treated five times per week and induced by a 10(-1) dilution of the virus (group B) was 18. Likewise the GMD (mm) of papillomas treated once per week was 18 (group D). On the other hand, we found that soaking plus the use of a grooved needle plus podofilox resulted in the curing of all lesions induced by a 10(-2) virus dilution and of most induced by the 10(-1) dilution, whereas soak plus podofilox or podofilox alone were not as effective in curing the lesions. Podofilox plus needle approached the soak plus podofilox plus needle in effectiveness. Treatment schedule was not a critical determinant of podofilox effectiveness. Therapeutic benefits were enhanced by hydration of the overlying cutaneous horn and penetration with a grooved needle.
Kreider
J W
JW
Department of Pathology, Milton S. Hershey Medical Center, Pennsylvania State University, Hershey 17033.
Pickel
M D
MD
D000287:Administration, Topical; D000818:Animals; D004334:Drug Administration Schedule; D016503:Drug Delivery Systems; D004867:Equipment Design; D005260:Female; D007101:Immersion; D007279:Injections, Subcutaneous; D008297:Male; D009339:Needles; D010212:Papilloma / Q000188:drug therapy* / Q000382:microbiology; D027383:Papillomaviridae; D011034:Podophyllotoxin / Q000008:administration & dosage* / Q000627:therapeutic use*; D011817:Rabbits; D012878:Skin Neoplasms / Q000188:drug therapy* / Q000382:microbiology
D011034:Podophyllotoxin